

# Peru

Population 2015

31 million

Estimates of TB burden*, 2015	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	2 (1.6–2.4)	6.2 (4.9–7.7)
Mortality (HIV+TB only)	0.49 (0.34–0.67)	1.6 (1.1–2.2)
Incidence (includes HIV+TB)	37 (29–47)	119 (92–150)
Incidence (HIV+TB only)	2.3 (1.7–2.9)	7.2 (5.5–9.1)
Incidence (MDR/RR-TB)**	3.2 (2.7–3.8)	10 (8.6–12)

Estimated TB incidence by age and sex (thousands)*, 2015			
	0-14 years	> 14 years	Total
Females	1.7 (0.85–2.5)	13 (7.9–18)	15 (8.7–21)
Males	1.7 (1.1–2.4)	21 (16–26)	23 (17–28)
Total	3.4 (2.4–4.5)	34 (29–39)	37 (29–47)

TB case notifications, 2015	
Total cases notified	30 988
Total new and relapse	29 833
- % tested with rapid diagnostics at time of diagnosis	86%
- % with known HIV status	81%
- % pulmonary	81%
- % bacteriologically confirmed among pulmonary	82%

Universal health coverage and social protection	
TB treatment coverage (notified/estimated incidence), 2015	80% (64–100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2015	0.07 (0.05–0.09)

TB/HIV care in new and relapse TB patients, 2015		
	Number	(%)
Patients with known HIV-status who are HIV-positive	1 459	6%
- on antiretroviral therapy	952	65%

Drug-resistant TB care, 2015			
	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			2 000 (1 900–2 100)
Estimated % of TB cases with MDR/RR-TB	5.9% (5.6–6.3)	21% (19–22)	
% notified tested for rifampicin resistance	70%	87%	25 670
MDR/RR-TB cases tested for resistance to second-line drugs			996
Laboratory-confirmed cases		MDR/RR-TB: 1 534, XDR-TB: 74	
Patients started on treatment ****		MDR/RR-TB: 1 738, XDR-TB: 56	

Treatment success rate and cohort size		
	Success	Cohort
New cases registered in 2014	87%	15 171
Previously treated cases registered in 2014	74%	2 363
HIV-positive TB cases, all types, registered in 2014	68%	996
MDR/RR-TB cases started on second-line treatment in 2013	55%	1 261
XDR-TB cases started on second-line treatment in 2013	66%	53

TB preventive treatment, 2015	
% of HIV-positive people (newly enrolled in care) on preventive treatment	70%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	68% (63–75)

TB financing, 2016	
National TB budget (US\$ millions)	86
Funding source: 87% domestic, international, 13% unfunded	

\* Ranges represent uncertainty intervals


\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

\*\*\* Includes cases with unknown previous TB treatment history

\*\*\*\* Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed


## Tuberculosis profile

(Rate per 100 000 population per year)




Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




Incidence  
Notified (new and relapse)  
Incidence (HIV+TB only)

Notified cases by age group and sex, 2015




Treatment success rate (%)



New cases  
Previously treated cases  
HIV-positive MDR/RR-TB XDR-TB

Total budget (US\$ millions)



Unfunded  
Funded internationally  
Funded domestically